Administer orally, usually using a calibrated oral syringe or dropper to ensure accurate dosing for pediatric patients. Can be taken with or without food. Ensure the full prescribed dose is taken.

Abacavir is a carbocyclic synthetic nucleoside analogue. It is intracellularly phosphorylated to its active metabolite, carbovir triphosphate. Carbovir triphosphate inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxyguanosine-5'-triphosphate and by incorporating into viral DNA, resulting in chain termination. This prevents further replication of the viral DNA.

• •Hypersensitivity to abacavir or any component of the formulation.
• •Patients positive for HLA-B*5701 allele due to high risk of hypersensitivity reaction (severe, potentially fatal).
• •Severe hepatic impairment.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze. Keep bottle tightly closed. Protect from light.

Limited experience with abacavir overdose. No specific antidote available. Treatment should be supportive and symptomatic, with monitoring of vital signs and clinical status.

Pregnancy: Registry data suggests no increased risk of major birth defects with abacavir exposure during pregnancy. Use during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus. Lactation: Abacavir is excreted into breast milk. HIV-infected mothers should not breastfeed to avoid transmitting HIV to the infant.